Qiagen Kept at Hold as Guidance Cut and QuantiFERON Weakness Offset H2 Rebound Hopes and Heighten Execution Risk

William Blair analyst Andrew Brackmann has maintained their neutral stance on QGEN stock, giving a Hold rating today.

Andrew Brackmann has given his Hold rating due to a combination of factors related to Qiagen’s recent performance and outlook. The company’s preliminary first‑quarter results fell short of expectations, with revenue and QuantiFERON sales disappointing as immigration‑driven testing volumes in key regions like the U.S. and the Middle East declined, and management cut both full‑year revenue growth and earnings guidance.

At the same time, the revised outlook for the second half of the year assumes a rebound that depends on successful product launches, better QuantiFERON trends, improved U.S. life sciences spending, and contributions from new initiatives, all of which introduce meaningful execution risk amid ongoing questions about strategic options and the CEO transition. Given these uncertainties and a valuation around 16 times updated 2026 earnings, Brackmann sees neither a compelling upside catalyst nor a clear reason for significant downside, supporting his decision to maintain a neutral Hold stance on the stock.

In another report released today, Barclays also maintained a Hold rating on the stock with a $44.00 price target.